Results 171 to 180 of about 59,025 (322)
Potential of AON therapy targeting AASS: A promising molecular therapy for pyridoxine-dependent epilepsy. [PDF]
Salih MA.
europepmc +1 more source
Neonatal Hypoglycemia, Lactic Acidosis, and Pyridoxine-Dependent Epilepsy [PDF]
J Gordon Millichap
openalex +1 more source
Treatable Neonatal Molybdenum Cofactor Deficiency: Rapid Demise Despite Rapid Biochemical Diagnosis
ABSTRACT Molybdenum cofactor deficiency (MoCD) is an inborn error of metabolism included in the differential for refractory neonatal seizures. The prognosis is guarded, with a median reported age of death between 2.4 and 3.0 years. Mortality is primarily due to seizures and lower respiratory tract infections.
Molly M. Crenshaw +11 more
wiley +1 more source
Hepatocellular Carcinoma: A Critical Complication in Patients Treated with Pyridoxal Phosphate. [PDF]
Brands MM +14 more
europepmc +1 more source
A Multifunctional Oxovanadium(V) Schiff Base Complex: Integrated Pyridoxine Sensing and Anticancer and Antimicrobial Activities. [PDF]
Kohanfekr T, Hosseini HA.
europepmc +1 more source
Bacteriocinogenic Staphylococcus epidermidis ST0409KOC was isolated from cheese and characterized as bacteriocin‐producing with strong activity versus Listeria monocytogenes and other pathogens. S. epidermidis ST0409KOC can be considered a safe strain regarding its virulence genetic background, presenting only a single virulence gene of IS257 among the
Kayque Ordonho Carneiro +2 more
wiley +1 more source
Safety and Effectiveness of Long-Term Isoniazid Treatment for the Prevention of Tuberculosis in High-Risk Dialysis Patients. [PDF]
Freercks R +8 more
europepmc +1 more source

